Details

Autor(en) / Beteiligte

• Wensink, G Emerens
• Elferink, Marloes A G
• May, Anne M
• Mol, Linda
• Hamers, Patricia A H
• Bakker, Sandra D
• Creemers, Geert-Jan
• de Groot, Jan Willem B
• de Klerk, Gerty J
• Haberkorn, Brigitte C M
• Haringhuizen, Annebeth W
• Hoekstra, Ronald
• Hunting, J Cornelis B
• Kerver, Emile D
• Mathijssen-van Stein, Danielle
• Polée, Marco B
• Pruijt, Johannes F M
• Quarles van Ufford-Mannesse, Patricia
• Radema, Sandra
• Rietbroek, Ronald C
• Simkens, Lieke H J
• Tanis, Bea C
• Ten Bokkel Huinink, Daan
• Tjin-A-Ton, Manuel L R
• Tromp-van Driel, Cathrien S
• Troost, Monique M
• van de Wouw, Agnes J
• van den Berkmortel, Franchette W P J
• van der Pas, Anke J M
• van der Velden, Ankie M T
• van Dijk, Marjan A
• van Dodewaard-de Jong, Joyce M
• van Druten, Edith B
• van Voorthuizen, Theo
• Jan Veldhuis, Gerrit
• Verheul, Henk M W
• Vestjens, Hanneke J H M J
• Vincent, Jeroen
• Kranenburg, Onno W
• Punt, Cornelis J A
• Vink, Geraldine R
• Roodhart, Jeanine M L
• Koopman, Miriam

Titel

Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era

Ist Teil von

• British journal of cancer, 2021-01, Vol.124 (2), p.399-406

Ort / Verlag

England: Nature Publishing Group

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Electronic Journals Library - Freely accessible e-journals

Beschreibungen/Notizen

• Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy. Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified. Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8-19.6) with antitumour therapy and 2.5 months (1.8-3.5) in untreated patients. OS1 was 12.8 months (10.7-15.2) and OS2 6.2 months (5.4-8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients. Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients.